Morningstar

Front Month Nymex ULSD Rose 9.03% This Month to Settle at $4.4937 — Data Talk

Provided by Dow Jones

Front Month Nymex ULSD for Sept. delivery gained 37.22 cents per gallon, or 9.03% to $4.4937 this month 




       --Up for two consecutive months 



       --Up $1.1769 or 35.48% over the last two months 



       --Largest two month net and percentage gain since April 2026 



       --Today it is up 13.70 cents or 3.14% 



       --Largest one day dollar and percentage gain since Monday, Aug. 17, 2026 



       --Up for four consecutive sessions 



       --Up 24.99 cents or 5.89% over the last four sessions 



       --Largest four day dollar and percentage gain since Thursday, Aug. 13, 2026 



       --Longest winning streak since Friday, Aug. 21, 2026, when the market rose for six straight sessions 



       --Up 16 of the past 19 sessions 



       --Today's settlement value is the fourth highest this year 



       --Highest settlement value since Friday, Aug. 21, 2026 



       --Off 2.49% from its 52-week high of $4.6084 hit Friday, March 20, 2026 



       --Up 118.49% from its 52-week low of $2.0567 hit Wednesday, Jan. 7, 2026 



       --Rose 98.25% from 52 weeks ago 



       --Off 2.49% from its 2026 settlement high of $4.6084 hit Friday, March 20, 2026 



       --Up 118.49% from its 2026 settlement low of $2.0567 hit Wednesday, Jan. 7, 2026 



       --Off 12.50% from its record high of $5.1354 hit Thursday, April 28, 2022 



       --Year-to-date it is up $2.3731 or 111.91% 





     All prices are calculated based on the settlement price of the current front month contract. 





     Source: Dow Jones Market Data 





  (END) Dow Jones Newswires



  August 31, 2026 15:11 ET (19:11 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
 
Plus, a deep dive on SpaceX’s bid to challenge US telecoms. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
6 ETFs To Diversify Away From AI
 
A difficult problem has an easy solution. 
 
 
Daniel Sotiroff 
 
 
 
Are TIPS ETFs the Best Way to Fight Inflation?
 
Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing. 
 
 
Daniel Sotiroff and Ivanna Hampton 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
3 New 5-Star Stocks This Week
 
PayPay and CRISPR are now seen as significantly undervalued. 
 
 
Bella Albrecht 
 
 
 
 

			Sponsor Center